Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Sep;9(5):368-76.
doi: 10.1007/s11910-009-0054-1.

An update on treatment and prevention strategies for Alzheimer's disease

Judith Neugroschl  1 , Mary Sano
Affiliations
Review

An update on treatment and prevention strategies for Alzheimer's disease

Judith Neugroschl et al. Curr Neurol Neurosci Rep. 2009 Sep.

Abstract

With the aging of the population, the incidence and prevalence of Alzheimer's disease will grow, increasing the burden on individuals and society. While ameliorating symptoms, the currently available treatments approved by the US Food and Drug Administration do not halt progression or cure the illness. This article discusses recent data on treatment strategies targeting amyloid and tau pathology. Novel therapeutic strategies such as inhibitors of receptors for advanced glycation end products (RAGE), potential mitochondrial modification with Dimebon, anti-inflammatory approaches, and cholesterol-lowering agents are also reviewed. An update on results from pharmacologic and nonpharmacologic prevention trials is provided.

PubMed Disclaimer

Conflict of interest statement

Disclosure

No potential conflicts of interest relevant to this article were reported.

References

    1. Barten DM, Albright CF: Therapeutic strategies for Alzheimer’s disease. Mol Neurobiol 2008, 37:171–186. - PubMed
    1. Nicoll JA, Wilkinson D, Holmes C, et al.: Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003, 9:448–452. - PubMed
    1. Gilman S, Koller M, Black RS, et al.: Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553–1562. - PubMed
    1. Elan: Elan and Wyeth to Initiate Phase 3 Clinical Trial of Bapineuzumab (AAB-001) in Alzheimer’s Disease. Available at http://www.elan.com/news/2007/20070521.asp Accessed June 23, 2009.
    1. Wyeth: Elan and Wyeth Announce Encouraging Top-Line Results from Phase 2 Clinical Trial of Bapineuzumab for Alzheimer’s Disease. Available at http://www.wyeth.com/news?nav=display&navTo=/wyeth_html/home/news/pressr... Accessed June 23, 2009.

MeSH terms

Substances